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Abstract: Melatonin exerts its actions through membrane MT1/MT2 melatonin receptors, 
which belong to the super family of G-protein-coupled receptors consisting of the typical 
seven transmembrane domains. MT1 and MT2 receptors are expressed in various tissues of 
the body either as single ones or together. A growing literature suggests that the 
melatonergic system may be involved in the pathophysiology of mood and anxiety 
disorders. In fact, some core symptoms of depression show disturbance of the circadian 
rhythm in their clinical expression, such as diurnal mood and other symptomatic variation, 
or are closely linked to circadian system functioning, such as sleep-wake cycle alterations. 
In addition, alterations have been described in the circadian rhythms of several biological 
markers in depressed patients. Therefore, there is interest in developing antidepressants 
that have a chronobiotic effect (i.e., treatment of circadian rhythm disorders). As melatonin 
produces chronobiotic effects, efforts have been aimed at developing agomelatine, an 
antidepressant with melatonin agonist activity. The present paper reviews the role of the 
melatonergic system in the pathophysiology of mood and anxiety disorders and the clinical 
characteristics of agomelatine. Implications of agomelatine in “real world” clinical practice 
will be also discussed. 
Keywords: melatonin; melatonergic receptors; serotonin; dopamine; noradrenaline; 
agomelatine; major depression; anxiety 
 
1. Anatomy and Physiology of the Brain Melatonergic System 
The neurohormone melatonin (N-acetyl-5-methoxytryptamine) is prominently, albeit not exclusively, 
synthesized in the pineal gland and is secreted in a phasic manner, since its circulating levels vary in a 
daily cycle. Melatonin derives from the precursor tryptophan (taken up from circulating blood) by 
subsequent steps, implicating tryptophan transformation in serotonin, N-acetylserotonin and, finally, in 
melatonin [1]. Transformation of serotonin in melatonin is regulated by the light-dark cycle, since 
enzymatic activity of N-acetyltransferase (the rate limiting biosynthetic enzyme) is low during daytime 
or under exposure to light stimuli and higher during dark phases.  
Once synthesized, melatonin is released both in the cerebrospinal fluid and in the capillary, which 
distributes the hormone in multiple body tissues [2]. Melatonin exerts pleiotropic actions on several 
body compartments and organs; however, these actions are beyond the scope of this review, and the 
reader is referred to other reviews for more information [3]. Melatonin is regarded as a “chronobiotic” 
hormone, since it regulates several chronobiological actions and is, in particular, responsible for 
circadian phase shifting. However, under conditions of total darkness (especially in the Arctic or 
Antarctic winter, where there is effectively no sunlight for several months), melatonin may still exhibit 
a diurnal rhythm, albeit that the rhythms become desynchronized. The melatonin-mediated effects are, 
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in turn, under the control of a group of hypothalamic nuclei, mostly the suprachiasmatic nucleus 
(SCN), which is considered an endogenous circadian pacemaker [4,5]. In seasonal breeders,  
moreover, melatonin effects are also mediated by the pars tuberalis (PT), which is implicated in  
photoperiodically-regulated reproduction and the premammillary hypothalamus.  
Among the more relevant biological functions exerted by melatonin are the control of the  
sleep-wake cycle, the modulation of the immune system (including anti-inflammatory properties) and of 
energy metabolism [6]. Melatonin interacts with at least two receptor types, named MT1 and  
MT2 [7–11], although adjunctive binding sites have also been described [12,13].  
Melatonin receptors belong to the class of G-protein-coupled receptors and are primarily expressed 
in the CNS; however, they are also widely distributed in other body tissues, together and separately. 
Within the CNS, the MT1 receptor is prominently expressed in the SCN, the hippocampus, the retina, 
the caudate putamen, the nucleus accumbens, the substantia nigra and the ventrotegmental area [7,14]. 
Notably, most of these areas belong to the central dopaminergic pathways, suggesting a tight 
correlation between the melatonergic and monoaminergic systems, at least the dopaminergic one. MT1 
receptors are also found in several other hypothalamic nuclei and brain areas, such as the 
paraventricular nucleus, the periventricular nucleus, the supraoptic nucleus, the diagonal band of 
Broca, the Meynert nucleus, the tuberomammillary nucleus and the mammillary bodies [14]. The MT2 
receptor has been mostly found in the hippocampus, the SCN and the retina [7]. Outside the CNS, 
MT1 receptors are thoroughly distributed in several tissues, while expression of MT2 receptors is more 
restricted [7]. Expression of both MT1 and MT2 receptors has also been reported in neurons and glial 
cells of the cortex, thalamus and cerebellar cortex. Moreover, both receptors are expressed in the 
pineal gland [15], which is consistent with reported melatonin autocrine and paracrine actions.  
Intriguingly, expression of melatonin receptors in both central and peripheral tissues is affected on a 
circadian basis, since mRNA expression of the MT1 receptor has been found to be increased in rodents 
during daytime [16]. Binding to the MT1 receptor was also found to be increased during the daytime 
and by light exposure during the nighttime, while MT1 mRNA expression was reduced by this latter 
procedure [15]. Despite an increase in mRNA expression during the daytime, however, surface 
expression of the melatonergic receptor in SCN neurons has been reported to be very low during the 
day and high at night, paralleling melatonin’s trough and peak [17]. These findings suggest that the 
levels of circulating melatonin elicit a feedback regulation on the surface receptor amount, causing a 
downregulation of receptors with blood peaks. At the same time, surface receptors are more expressed 
when melatonin levels are expected to be higher and vice versa. This group of feedback regulations 
allows the system to preserve its homeostasis and to provide fine-regulation with external light-dark 
stimuli. However, regulation of melatonin receptor expression is under multiple other biological 
factors, e.g., estradiol levels, which cooperate to modulate melatonergic signaling in its different steps.  
MT1 receptor signaling occurs mainly through interaction with inhibitory G-proteins and 
subsequent reduction of intracellular cAMP levels, a decrease in protein kinase A activity and reduced 
phosphorylation of the transcription factor, CREB [18]. However, in an artificial system, i.e., cultured 
cells, melatonin has also been demonstrated to increase cAMP levels via interaction with the MT1 
receptor [19], although the actual relevance of these in vivo observations remains questionable.  
MT2 receptors couple to multiple and diverse transduction pathways, depending on the biological 
system taken into consideration and ranging from inhibition of cAMP synthesis to the increase of 
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protein kinase C activity or from inhibition of guanylyl cyclase signaling to increase cGMP  
levels [20–22].  
At the subcellular level, melatonin modulates the activity of a number of ion channels and affects 
intracellular ion levels [23,24]. The hypothalamic SCN and the hippocampus are two major sites of 
melatonin action in the CNS. The SCN activity is inhibited by melatonin via MT1 receptors [25], 
mostly during the daytime, when the SCN neuronal activity is higher. However, melatonergic 
inhibition of SCN activity is blunted by melatonin itself through the regulation of surface receptor 
expression [26] by their desensitization. Desensitization occurs after exposure to melatonin by a  
beta-arrestin-1-dependent mechanism [27], requiring a phosphorylation on the MT1 and MT2 receptor  
C-terminal [28]. Melatonergic receptor desensitization is mainly associated to receptor downregulation. 
Prevention of melatonergic receptor desensitization has been obtained by depolymerizing microtubules 
and the blockade of receptor internalization [29]. However, in SCN cells, exposure to physiological 
concentrations of melatonin caused the reversible desensitization and downregulation of MT2 
receptors and the desensitization of MT1 receptors, however, without their downregulation [30]. 
Therefore, multiple molecular mechanisms may concur to diminish melatonin-mediated signaling.  
In the hippocampus, melatonin has been reported to increase the firing rate of CA1 neurons through 
activation of MT2 receptors [30]. In hippocampal slices, melatonin disrupted long-term potentiation in 
a dose-dependent fashion [30]. Both effects were prevented by application of a MT2 receptor 
antagonist and were lacking in MT2 gene knock-out mice, but not in MT1 defective mice [31]. 
Melatonergic signaling via the MT2 receptor in hippocampus has been described to substantially affect 
cognitive behavior in preclinical paradigms. Knock-out mice for the MT2 gene were found to perform 
worse than wild-type littermates at the elevated plus-maze behavioral task, a procedure investigating 
learning and memory abilities [32], possibly implying an impairment in hippocampal-mediated 
synaptic plasticity. It has also been demonstrated that agomelatine, a potent melatonin receptor agonist 
drug that strongly binds to and stimulates the activity of melatonin MT1 and MT2 receptors, showed 
cognitive enhancing properties, at least in preclinical studies [33,34]. 
The physiology of melatonergic signaling has been elucidated only in part. In mammals, melatonin 
exerts a main action on phase shifting, which reflects a feedback loop between the pineal gland and the 
endogenous circadian pacemaker, i.e., the SCN [3]. Within this feedback loop, melatonin controls the 
amplitude and phase of circadian oscillation. Namely, the hormone exerts phase shifting via MT2 
receptors and affects neuronal firing by MT1 receptors [35]. In functional agreement with these actions, 
melatonin also favors sleep initiation by a number of mechanisms, including MT1 receptor-mediated 
effects on the hypothalamic sleep switch [36] and modulation of discrete thalamic projections to the 
cortex that are implicated in sleep stage transitions [37]. Moreover, melatonin also takes part in 
sedating and anxiolytic effects.  
Recently, Ochoa-Sanchez et al. [38] demonstrated that the melatonin MT2 receptor was involved in 
the regulation of non-REM (NREM) slow wave sleep (SWS), and the MT2 selective agonist, 
UCM765, increased NREM by activating the reticular thalamus neurons, where the MT2 receptors are 
located. The melatonin MT2 receptor also mediates anxiety function [39]. On the other hand,  
it has been demonstrated that the melatonin MT1 receptor is mostly involved in the control of  
REM sleep [40]. 
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2. Interactions between Melatonergic System and Monoaminergic Systems 
The main role of the pineal gland is to produce melatonin in response to the absence of light stimuli, 
which may, in turn, activate a glutamate-mediated response from retinal receptors to SCN GABAergic 
neurons, thereby generating an environment-to-endocrine input translation that is at the basis of 
circadian rhythms in humans [41]. Located in the middle of the brain, although externally to the  
blood-brain barrier, the pineal gland represents a powerful triage organ, where neurotransmission 
signals from the SCN are converted to endocrine secretion, which, in turn, may regulate other 
monoaminergic neurotransmitter systems, such as dopamine, norepinephrine and serotonin. For 
instance, recent reports demonstrated that chronic melatonin treatment in animal models of aging may 
help normalize levels of all monoamines, such as dopamine, serotonin and norepinephrine, thus 
contrasting age-related impairment in catecholamines neurotransmission [42].  
Here, we review the complex interconnections between catecholaminergic systems and melatonin 
neuroendocrine secretion. 
2.1. Serotonin Is the Main Controller of Circadian Clocks 
Melatonin secretion is obviously tightly dependent on the availability of serotonin in pinealocytes. 
Since serotonin is the precursor of melatonin, this neurotransmitter is, indeed, the principal actor of the 
light/dark circadian regulation of melatonin secretion [43]. The SCN contains a hyper-dense 
serotonergic terminal plex [44]. Early studies demonstrated that serotonin administration or 
serotonergic agonist agents may phase-shift the circadian SCN pacemaker [45]. Moreover, lesions in 
the raphe nuclei may cause a decrease in circadian amplitude or a phase change [43]. Several studies 
demonstrated multiple mechanisms of modulation by serotonin receptors on the circadian clock. 
Serotonin, indeed, may postsynaptically increase potassium currents in a subset of SCN neurons, in 
order to alter circadian phases [46]. Moreover, SCN-evoked currents may be presynaptically inhibited 
by serotonin, through a direct reduction in excitatory stimuli originating from the retinal tract [42]. 
However, more recent reports demonstrated a more complex regulation of SCN rhythms by serotonin. 
Indeed, serotonin agonists are able to phase-shift circadian clocks only when serotonin release has 
been previously decreased or in in vitro environments devoid of serotonin concentrations. When 
serotonergic agents are pre-applied to SCN neurons, a new application of serotonin is less able to 
phase shift the circadian clock, thereby demonstrating that the SCN is affected by serotonin only, 
depending on the pre-existent serotonergic signaling [47]. Substantially, serotonin may act as a 
synchronizer with the same effects as light on SCN neurons [48]. Indeed, synchronization of circadian 
clocks by both light and serotonin coincide with modulation of specific clock genes, Per1 and  
Per2 [49–51]. However, synchronizing effects of serotonin on circadian rhythms have been 
demonstrated to occur only at daytime. When administered at nighttime, serotonin may only modulate 
light-induced phase-shifts in clock genes, but is not able to phase-shift clocks by itself [52]. Recent 
studies demonstrated that the reasons for this “paradox” reside in the light/dark-dependent differential 
expression of serotonergic-specific receptors in the SCN [53]. 
Emerging evidence supports the view that melatonin may also regulate serotonin secretion in a 
retrograde circadian feedback loop. Serotonin, indeed, is also secreted by raphe nuclei with a clear 
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downward trend during the night and an upward increase in the daytime [54]. Melatonin, on the other 
hand, may inhibit raphe neuron firing, possibly through acting on MT1 receptors [55].  
2.2. Norepinephrine Controls Limiting Steps of Enzymatic Melatonin Production 
Several studies demonstrated that melatonin secretion is not tightly dependent upon light, since in 
complete darkness, melatonin is produced by SCN-triggered stimulus. Circadian rhythms are 
synchronized by light-dark cycles. 
The limiting enzymatic step of melatonin production in pinealocytes is the N-acetylation of 
serotonin by aryl-alkylamine-N-acetyl-transferase (AANAT), which has been demonstrated to increase 
its functioning levels at night [56]. In fact, it is possible to assume that AANAT functioning is the real 
circadian clock at the pineal gland level. 
Several studies have demonstrated that the nocturnal increase in melatonin secretion is directly 
related to norepinephrine nightly release by SCN to pineal gland. Norepinephrine, indeed, may 
stimulate alpha- and beta-adrenergic pineal receptors, which, in turn, trigger a cAMP-dependent 
increase in PKA intracellular activity that induces the CREB-mediated transcription of AANAT  
protein [57]. This cascade provides a rapid increase in AANAT activity, which results in melatonin 
formation in a 2 h time range after norepinephrine stimulus. However, other norepinephrine-related 
mechanisms have been implicated in melatonin secretion control. Indeed MAPK activation by 
adrenergic receptors has also been involved in AANAT pinealocytes responses [58]. Moreover, 
adrenergic signaling has been demonstrated to modulate histone deacetylation and phosphorylation by 
means of a MAPK-dependent mechanism, which suggests a further control on AANAT functioning 
(for a review, see [59]).  
Emerging evidence suggests that norepinephrine control of melatonin secretion may be under a 
dynamic presynaptic control. Indeed, early studies demonstrated that, besides SCN innervation, the 
pineal gland receives projections from sphenopalatine, otic and trigeminal ganglia [60], which have 
been reported to secrete substance P [61]. Recent works demonstrated that pinealocytes are enriched 
with substance P receptors [62] and that substance P may inhibit norepinephrine-induced AANAT 
activation and melatonin secretion, though it does not impair basal levels of AANAT functioning [63]. 
As a further suggestion of presynaptic control of norepinephrine-mediated melatonin activity, Koch 
and coworkers recently demonstrated that phytocannabinoids (e.g., tetrahydrocannabinol) application 
to rat pineal gland cultures may reduce stimulation of melatonin secretion by norepinephrine [64]. 
Further studies by the same group recognized endocannabinoid receptors and metabolizing  
enzymes in pinealocytes, thereby demonstrating a possible endocannabinoid-dependent control of  
norepinephrine-stimulated melatonin secretion [65]. 
Conversely, some hormones, such as insulin, may enhance norepinephrine-mediated melatonin 
synthesis and AANAT activity [66].  
2.3. Melatonin-Dopamine Reciprocal Interactions: Molecular Bases for Neuropsychiatric  
Disorder Pathophysiology 
Emerging evidence supports the bi-univocal relation between melatonergic and dopaminergic 
transmission. Dopamine, indeed, is present in sympathetic nerves projecting to the pineal gland, not 
Int. J. Mol. Sci. 2013, 14 12464 
 
 
only as a precursor of norepinephrine, but also as a neurotransmitter, which has been demonstrated to 
have a crucial role in melatonin secretion control. Indeed, pinealocytes express high levels of 
dopamine D4 receptors (D4R), whose expression has the singular ability of being dynamically 
regulated in the pineal gland based on night/day circadian retinal synchronization [67]. Recent 
evidence demonstrated that D4R expression is directly controlled by norepinephrine action at  
alpha1- and beta1-adrenergic receptors, since beta-adrenergic agonists may increase D4Rs on the 
pinealocyte cell surface [68]. Notably, D4R expression in pinealocytes seems to be controlled by a 
“double gate” mechanism, which requires the thyroid hormone-mediated activation of II iodothyronine 
deiodinase (Dio2), which transforms T4 into T3 active hormone, which acts simultaneously on the 
adrenergic-mediated cAMP formation at the basis of D4R translation [67].  
Therefore, dopamine seems to exert a complex modulatory control on melatonin synthesis, highly 
dependent on light/dark cycles. Recent evidence demonstrated an entangled mechanism by which 
dopamine may regulate norepinephrine-dependent melatonin secretion. D4R, indeed, may form 
heteromeric complexes with both alpha1- and beta1-adrenergic receptors. These heteromers, whose 
formation is controlled by light–dark circadian rhythms, may enable D4R to modulate the  
adrenergic-mediated activation of MAPK and Akt cascades, which, in turn, promote melatonin 
synthesis and secretion [69]. 
On the other hand, melatonin has been demonstrated to control dopamine signaling in selected  
regions of the forebrain. Indeed, melatonin may inhibit dopamine release in hypothalamic areas 
(tuberoinfundibular region), as well as in ventral hippocampus [70]. The decrease in dopamine 
concentrations in these areas occurs simultaneously with a concurrent increasing in tyrosine 
hydroxylase activity [71]. Melatonin seems also able to reduce cortical glutamate-mediated stimulation 
of striatal responses [72]. These effects may be directly dependent on the reduction in dopamine 
striatal release by nigrostriatal fibers induced by melatonin. Moreover, it has been demonstrated that 
melatonin may directly reduce NMDA glutamate receptor functions in striatal neurons, thereby 
reducing NMDA-mediated long-term synaptic responses in this brain region [73]. Other studies 
demonstrated that melatonin may directly act on dopaminergic receptor functions in the brain. Indeed, 
melatonin has been reported to increase dopamine D2 receptors (D2R) affinity in rat striatum [74]. In 
contrast, melatonin may dose-dependently counteract the dopamine D1 receptors (D1R)-mediated 
cAMP enhancement in neurons [75].  
Melatonergic receptors (MT1, MT2) are widely distributed in the brain, above all, in hippocampus, 
cortex, hypothalamus and cerebellum [76–78]. Moreover, melatonin receptors seem to have special 
relations with dopaminergic systems. Indeed, MT1 receptors are localized in ventral tegmental  
area and striatum (above all, nucleus accumbens shell). Surprisingly, these receptors have  
light/dark-dependent expression, with high levels during the night and low levels during the day [14]. 
This specific connection between melatonin receptors and dopaminergic sites may have an essential 
role in the pathophysiology of behavioral disorders that depends upon dopaminergic dysfunctions. 
Indeed, it has been demonstrated that cocaine reward sensitization yields a critical dependence on 
daylight, with pineal gland having a crucial role in this diurnal reward [79]. Moreover, pharmacological 
doses of melatonin may block the cocaine-induced diurnal behavioral sensitization [80]. Inversely, 
cocaine protracted administration may reduce MT1 receptor expression in striatum [81].  
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Last, melatonin has been demonstrated to have protective effects in animal models of dopaminergic 
dysfunctions, such as 6-hydroxydopamine-induced parkinsonisms [82] or rotenone-induced motor 
disturbances [83]. 
Recently, a significant association of the MT1 receptor haplotype ATG has been reported in 
antipsychotic-treated schizophrenic patients that do not develop tardive dyskinesia after prolonged 
treatments [84].  
3. Circadian Disturbances in Depression 
The complex relationships between the endogenous circadian pacemaker and the development of 
depressive symptoms are far from being elucidated [85]. The worsening of diurnal mood variation 
(DMV) with the early morning is a classic symptom of the melancholic features of major depressive 
disorder (MDD) and is one of the time-linked symptoms that has promoted speculation about the role 
of the circadian system in its pathogenesis [86]. MDD seems to be related to a disruption in the central 
circadian clock function and not to an alteration in a specific rhythm [85].  
In addition, the type of rhythm abnormality seems to be highly variable in depressed patients, 
including phase advance or phase delay of rhythms and increase or decrease in the rhythm  
amplitude [87]. There is substantial evidence that circadian rhythms are more attenuated in MDD than 
euthymic states, with decreased circadian amplitudes in core body temperature, motor activity, 
thyroid-stimulating hormone, norepinephrine (NE) and cortisol, as was found in several studies [88]. 
These decreased amplitudes might result from the weakened output of the endogenous oscillator and 
are one of the most relevant chronobiological abnormalities in depression that may be corrected by 
antidepressant drugs [87,88]. A phase advance of the rhythm of cortisol, adrenocorticotropin, prolactin 
and growth hormone has also been noted in depressed patients [85].  
4. Chronobiotic Properties of Agomelatine 
Agomelatine (Valdoxan®/Thymanax®) (S20098, N-[2-(7-methoxynaphth-1-yl)ethyl]acetamide) was 
first reported in the literature in 1992, among a series of synthetic naphthalene melatonin analogs. 
Various animal models of abrupt shifts and disorganization of the light-dark cycle, of free-running 
conditions, as well as of delayed sleep-phase syndrome have shown that agomelatine accelerates the 
resynchronization of circadian rhythms of locomotor activity and relevant biological parameters  
(i.e., body temperature, secretions of hormones) [33]. The resynchronizing activity of agomelatine has 
been mainly shown in both nocturnal (rats, mice, hamsters) and diurnal (Arvicanthis mordax) animals. 
The ability of agomelatine to synchronize rest-activity rhythms in free-running animals requires the 
integrity of the SCN [34].  
The accelerating effect of agomelatine was particularly notable if treatment was started three weeks 
prior to the induced phase shift [89,90]. Agomelatine treatment did not cause any major change in 
corticosterone or adrenocorticotropic hormone concentrations, vasopressin, corticotropin-releasing 
hormone and mineralocorticoid receptor mRNAs levels, which suggests that the mechanism of 
agomelatine action is not related to hypothalamic-pituitary adrenocortical axis changes. This study 
showed that agomelatine displays some characteristics of antidepressant drug action in the transgenic 
mouse model, effects that could be partially related to its chronobiotic properties [85]. 
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5. Pharmacodynamics and Pharmacokinetics of Agomelatine  
Agomelatine shows agonistic activity with high affinity for melatonin MT1 and MT2 receptors  
and an antagonist activity with moderate affinity for 5HT2C [91] (Figure 1). However, even if there is 
no question from the animal data that 5HT2C antagonism occurs, such antagonism in humans has been  
questioned [92,93]. 5HT1A and 5HT2B receptors are not thought to be responsible for agomelatine 
clinical effects, due to the low affinity of the drug for these receptors [94]. No significant affinity for 
any of the monoamine transporters or for adrenergic, noradrenergic, dopaminergic, muscarinic, 
histaminic and benzodiazepine receptors has been reported [95]. The binding affinity of agomelatine 
for MT1 and MT2 is similar to melatonin. The literature reported that antidepressant efficacy could be 
related to melatonin secretion through monoaminergic mechanisms [96,97], even if controversial data 
regarding blood melatonin concentrations in MDD were reported [98–104]. 
Figure 1. Mechanism of action of agomelatine (adapted from Srinivasan et al. [105]).  
 
Moreover, in experiments conducted on animals, agomelatine has demonstrated the ability to 
increase adult hippocampal and prefrontal cortex neurogenesis, to enhance expression of brain-derived 
neurotrophic factor (BDNF) and to trigger several cellular signals, i.e., protein kinase B (Akt), 
extracellular signal-regulated kinase 1/2 (ERK1/2) and glycogen synthase kinase 3β (GSK3β) [106]. It 
has also been reported that agomelatine may have beneficial effects on hippocampal neurogenesis in 
the stress-compromised brain of rats [107]. Most pre-clinical models suggested that either the 5HT2C 
antagonist effect or the MT1/MT2 agonist effects alone are not sufficient to account for the 
antidepressant properties of the drug, at least in predictive animal models [91–93]. Tardito et al. [108] 
proposed that the molecular-cellular effects of agomelatine and, therefore, its antidepressant activity, 
may be the result of a synergistic action between its agonism at MT1/MT2 and antagonism at  
5-HT(2C) receptors. The antidepressant properties of agomelatine, related to its effect on 
neurogenesis, cell survival, BDNF, activity-regulated cytoskeleton associated protein (Arc) and  
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stress-induced glutamate release, are due to this synergistic action. Intriguingly, agomelatine is the 
only one able to resynchronize these effectors at distinct levels, circuital and intracellular [102]. 
After oral administration, agomelatine is rapidly (Tmax ranging from 0.5 to 4 h) and well absorbed 
(80%), but its bioavailability is relatively low (<5% at the therapeutic oral dose) due to its high  
first-pass metabolism [109,110], which may be of concern, especially in elderly patients or in subjects 
with liver disorders. In humans, agomelatine has a moderate volume of distribution of approximately 
35 L, a plasma protein binding of 90%–94% (albumin and alpha L-acid glycoprotein) and a short 
plasma half-life (1–2 h) [111]. At therapeutic levels, agomelatine blood concentration increases 
proportionally with dose; at higher doses, a saturation of the first-pass effect may occur. The 
bioavailability is 2-fold higher for women compared to men [97]. About 90% of agomelatine is 
metabolized by cytochrome P450 (CYP) 1A2 (hydroxylation) and about 10% by CYP 450 2C9 
(demethylation) isoforms. At higher serum concentrations, also CYP 450 2C19 is involved in 
metabolism. Metabolites are conjugated with glucuronic acid and then sulfonated. About 80% of the 
drug is eliminated through urinary excretion of the metabolites (61%–81% of the dose in humans), 
whereas a small amount of the metabolites undergoes fecal excretion [112]. 
6. Agomelatine in the Treatment of Major Depressive Disorder 
Major depressive disorder is one of the most disabling and common psychiatric disorders. Recent 
data estimate a lifetime prevalence of MDD at 16.6% and the one-year prevalence at 6.7% [113–116]. 
MDD is a leading cause of premature death and ongoing disability [117,118]. Psychopharmacological 
treatments include a number of antidepressant drugs; however, over 60% of treated patients respond 
unsatisfactorily, and almost 20% of patients become refractory to the treatments [119–121]. Patients 
who respond satisfactorily to the treatments benefit from reduced suicide rates, increased participation 
in the workforce, reduced secondary alcohol or other substance misuse and decreased risk of 
cardiovascular disease [122,123]. In clinical studies, patients with a reduction of 50% or more on the 
Hamilton Depression Rating Scale (HAMD) total score at endpoint are considered responders to 
treatment; remission, which represents complete or near complete symptom resolution, including 
resolution of functional impairment, is commonly defined as an HAM-D total score of ≤7 [118]. 
6.1. Materials and Methods of Literature Review 
Searches of the Medline database from 1988 through August 2012 and the PsycInfo/Embase 
database from 1988 through January 2013 were carried out with the help of a professional librarian 
(M.C.), restricted to the English language. The search term “agomelatine” was combined with 
“depression”, “major depression”, “major depressive disorder”, “mood disorders”, “placebo”, 
“efficacy” and “adverse effects” to identify relevant original research and review articles. All citations 
were screened, and the full texts of peer-reviewed journal articles considered relevant to the purposes 
of the review were obtained. Furthermore, articles in press were included, if relevant. Bibliographies 
were scanned to locate additional relevant publications, even those older than 1988. 
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6.2. Acute Phase Trials with Agomelatine versus Placebo  
There are eight acute phase trial studies (five published and three unpublished) comparing 
agomelatine versus placebo (see Table 1). From published studies, three trials showed that agomelatine 
was more effective than placebo on the total HAMD score [124–126]; one trial reported that only  
50 mg of agomelatine provided a statistically significant improvement in the HAMD score from first 
baseline visit through week 8, whereas 25 mg of agomelatine did not [101]; one trial reported that  
25 mg of agomelatine was more efficacious based on the HAMD total score compared to placebo 
throughout the treatment period, whereas 50 mg of agomelatine did not [102]. 
From unpublished studies, one unpublished trial reported no significant differences in HAMD and 
Clinical Global Impression scale (CGI) scores in agomelatine versus placebo compared to fluoxetine 
versus placebo groups. (CL3-022) [97]; two studies (CL3-023 and CL3-024) were failed trials. 
6.3. Antidepressant Efficacy in Active Comparator Trials 
Agomelatine treatment efficacy, based on HAMD, CGI and the Montgomery-Asberg Depression 
Scale (MADRS), have been rated by several studies. Treatment with agomelatine systematically 
showed, at least, comparable efficacy with other antidepressants. Numerous studies have been 
conducted comparing agomelatine and venlafaxine. It is interesting that although antidepressant 
efficacy on HAMD was similar, CGI improvement was significantly higher and statistically significant 
for agomelatine compared to venlafaxine [127,128]. Based on MADRS scores at the end point for 
response and remission rates, antidepressant efficacy was similar in the two treatment groups [129]. 
After six weeks of treatment, the HAMD final score, as well as CGI was significantly better for 
agomelatine than for sertraline [130]. Over eight weeks, the mean decrease in HAMD total score was 
significantly greater with agomelatine than fluoxetine [131]. Based on HAMD scores, agomelatine was 
reported to be statistically non-inferior to escitalopram at six weeks [132]. 
One study compared the efficacy of agomelatine and sertraline in the treatment of depression and 
anxiety in depressed patients with type 2 diabetes mellitus [133]. Agomelatine was effective in the 
treatment of depression and anxiety, as well as in the improvement of health-related behaviors, in 
depressed patients with non-optimally controlled type 2 DM. 
6.4. Anhedonia in Major Depressive Disorder 
Anhedonia is defined as a loss of interest and lack of reactivity to pleasurable stimuli. It is 
considered a core symptom of MDD, a predictor of poor outcome [134], a common residual symptom 
after treatment [135] and associated with dysfunctions within the brain reward system [136,137]. In the 
first study where agomelatine was reported to be effective in the treatment of anhedonia,  
Di Giannantonio et al. found a significant improvement in the Snaith Hamilton Rating Scale  
(SHAPS) [138]. Moreover, after eight weeks of treatment, agomelatine showed a more relevant 
reduction compared to venlafaxine in SHAPS score [124].  
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Table 1. Published placebo-controlled and/or active comparator studies of agomelatine in the treatment of major depression. HAMD, 
Hamilton Depression Rating Scale. 
Authors Reference Study Design Comparator/Active 
Control 
Number of 
Patients 
Duration Agomelatine Dosage (mg/day) Results 
Loo et al., 2002 123 Placebo-controlled dose range 
study 
Placebo/Paroxetine  
20 mg/day 
711 8 weeks 1, 5 and 25  Agomelatine at 25 mg was statistically more 
effective than placebo 
Montgomery  
et al., 2004 
142 Randomized, double-blind,  
placebo-controlled 
discontinuation study 
Placebo/Paroxetine  
20 mg/day 
335 12 weeks 25 Agomelatine was effective and had less 
potential to cause discontinuation symptoms 
than paroxetine 
Kennedy & 
Emsley, 2006 
124 Randomized, double-blind,  
placebo-controlled study 
Placebo  212 6 weeks  25 and 50 Agomelatine at 25 mg was effective, but  
50 mg may be beneficial for some patients 
without reducing tolerability 
Lemoine et al., 
2007 
126 Randomized, double-blind 
comparison with venlafaxine 
study 
Venlafaxine  
75–150 mg/day  
334 6 weeks  25 and 50 Agomelatine showed similar antidepressant 
efficacy earlier and greater efficacy in 
improving subjective sleep as compared to 
venlafaxine 
Olié & Kasper, 
2007 
125 Double-blind, flexible dose, 
parallel-group, placebo controlled 
study 
Placebo  238 6 weeks 25 (with dose adjustment at two 
weeks to 50 mg/day in patients 
with insufficient improvement) 
Agomelatine was significantly more 
efficacious than placebo. Agomelatine had a 
safety profile similar to placebo 
Kennedy et al., 
2008 
128 Randomized, double-blind 
comparison with venlafaxine 
study 
Venlafaxine XR  
150 mg/day 
277 12 weeks  50 Agomelatine showed similar antidepressant 
efficacy with a superior sexual side effect 
profile to venlafaxine 
Goodwin et al., 
2009 
144 Randomized, double-blind,  
placebo-controlled study 
Placebo 339 24 weeks 25 and 50 Agomelatine was more effective than 
placebo and prevented relapses without 
evidence of discontinuation symptoms 
Hale et al., 
2010 
130 Randomized, double-blind 
comparison with fluoxetine study 
on severely depressed patients  
(HAMD ≥ 25) 
Fluoxetine  
20–40 mg/day 
515 8 weeks 25 and 50 Agomelatine was statistically more effective 
than fluoxetine 
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Table 1. Cont. 
Authors Reference Study Design Comparator/Active 
Control 
Number of Patients Duration Agomelatine 
Dosage 
(mg/day) 
Results 
Kasper et al., 
2010 
129 Randomized, double-blind 
comparison with sertraline 
study 
Sertraline  
50–100 mg/day 
313 6 weeks 25 and 50 Agomelatine was more effective than sertraline. 
Agomelatine improved the circadian rest-activity cycle 
more than sertraline 
Zajecka et 
al., 2010 
146 Multicenter, randomized, 
double-blind,  
placebo-controlled study 
Placebo 511 8 weeks 25 and 50 Agomelatine at 50 mg showed greater and rapid 
reduction in all core symptoms of depression compared 
with placebo 
Stahl et al., 
2010 
147 Randomized, double-blind, 
placebo-controlled study 
Placebo  503 8 weeks 25 and 50 Agomelatine at 25 mg was more effective than placebo 
over the course of the study, whereas agomelatine at  
50 mg provided evidence for its antidepressant efficacy 
until week six, but not at study end 
Quera-Salva 
et al., 2011 
131 Randomized, double-blind 
comparison with 
escitalopram study 
Escitalopram  
10–20 mg/day 
138 24 weeks 25 and 50 Agomelatine was as effective as escitalopram. 
Treatment with agomelatine improved morning 
condition and reduced daytime sleepiness compared 
with escitalopram 
Martinotti  
et al. 2012 
127 Open-label parallel-group, 
randomized comparison 
with venlafaxine study 
Venlafaxine  
75–150 mg/day 
60 8 weeks 25 and 50 Agomelatine antidepressant efficacy proved to be 
similar to that of venlafaxine during an eight-week 
treatment period 
Karaiskos  
et al. 2013 
132 Observational open label, 
randomized, comparison 
with sertraline study 
Sertraline  
50–100 mg/day 
40 depressed patients with 
non-optimally controlled 
type 2 diabetes mellitus 
(DM) 
4 months 25 and 50 Agomelatine was effective in the treatment of 
depression and anxiety, as well as in the improvement 
of health-related behaviors, in depressed patients with 
non-optimally controlled type 2 DM 
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6.5. Sleep in Major Depressive Disorder 
Sleep and daytime functioning are important aspects of major depressive disorder. Agomelatine 
showed an important difference in getting to sleep and quality of sleep in comparison with venlafaxine 
and sertraline [105]. Agomelatine was superior to venlafaxine, but no statistically significant 
difference was found when compared to sertraline in ease of awakening and integrity of behavior after 
awakening [117,120]. 
Two open-label studies evaluated agomelatine efficacy on sleep parameters in patients with  
MDD [139,140]. No change in rapid eye movement (REM) latency, amount of REM or REM density 
was observed. Agomelatine improved sleep continuity and quality, and it increased sleep efficiency, 
time awake after sleep onset and the total amount of SWS [128]. Agomelatine treatment improved 
very early NREM and REM sleep [129]. 
Recently, agomelatine has been evaluated on nighttime sleep and daytime condition compared to 
escitalopram [122]. Agomelatine was associated with reduction in sleep latency, preserved the number 
of sleep cycles and reduced daytime sleepiness. In a recent open-label study, 80% of patients with MDD 
receiving a flexible dose of agomelatine showed significant improvements at all visits in Leeds Sleep 
Evaluation Questionnaire (LSEQ) [127]. 
6.6. Sexual Function 
An important and non-negligible side effect of antidepressants is represented by sexual dysfunction. 
Kennedy et al. [118] found that treatment related sexual dysfunctions were significantly lower in the 
agomelatine group, whereas venlafaxine was associated with greater deterioration in the domains of 
desire and orgasm of the Sex Effects Questionnaire. In a randomized, placebo-controlled, eight-week 
study involving healthy male volunteers, agomelatine was shown to have better sexual acceptability 
than paroxetine. In fact, the Psychotropic Related Sexual Dysfunction Questionnaire (PRSEXDQ), 
reported better scores for agomelatine, similar to placebo, compared to paroxetine [141]. 
6.7. Anxiety Symptoms within Depression 
Anxiety symptoms are common in patients with MDD. Some trial studies evaluating agomelatine 
treatment efficacy in depressed patients reported Hamilton Anxiety (HAMA) scale scores. Final 
HAMA scores were similar when agomelatine was compared to paroxetine, fluoxetine and  
venlafaxine [114,117,118,121]. Agomelatine was superior in reducing HAMA scores compared to 
sertraline [120]. 
6.8. Discontinuation Symptoms 
Discontinuation symptoms in MDD have been evaluated in only one randomized, double-blind, 
placebo controlled study, with paroxetine as the active comparator [142]. No significant differences 
were present in the Discontinuation-Emergent Signs and Symptoms scale (DESS) between patients 
who stopped or continued agomelatine treatment. On the other hand, DESS scores were higher in 
patients discontinuing paroxetine, who reported insomnia, dreaming, dizziness, muscle ache, nausea, 
diarrhea, rhinorrhea and chills. These data suggest that agomelatine is not associated with 
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discontinuation symptoms. In an active comparator trial, discontinuation rates were fewer for agomelatine 
than venlafaxine, sertraline and fluoxetine [119–121], but similar to paroxetine [114]. 
6.9. Responders, Remitters and Relapse Prevention 
Remission is the final goal of antidepressant treatment. Six studies reported response and remission 
rates (three after six months of treatment and three in the acute phase). At six months, the efficacy of 
agomelatine was superior to venlafaxine in CGI scores [117], but no significant differences in the 
proportion of responders and remitters were found [117,119]. The responders’ proportion was superior 
for agomelatine compared to sertraline by HAMD, but no differences were found in the proportion of 
responders by CGI or remitters by HAMD or CGI [120]. Compared to placebo, in acute phase trials, 
response rates were significantly higher for agomelatine [114–116]. Only one study reported higher 
levels of remission rates for agomelatine after an eight-week treatment period [114]. Sparshatt et al. 
conducted a multicenter naturalistic evaluation of the use of agomelatine over a two-year period, in 
order to provide a picture of its clinical value in the treatment of depression [143]. Agomelatine was 
largely used in difficult-to-treat or refractory patients. After 12 weeks of treatment, a substantial 
number of patients improved by at least one point of the CGI (severity) scale. 
Two trial studies (one unpublished and one published) investigated long-term antidepressant effect 
of agomelatine treatment compared to placebo, regarding relapse prevention. The incidence of relapse 
over six months was significantly lower with agomelatine [144]. No significant differences in relapse 
rates were shown in the unpublished study (CL3-021) [97]. 
6.10. Serum Transaminases  
Servier Laboratories reported that agomelatine may cause a dose-related elevated liver function test 
(LFT), specifically serum transaminases >3-times the upper limit of normal [145]. The European 
Medicines Agency requires the monitoring of liver function during treatment at all doses [97]. 
Two studies reported notable aminotransferase elevations in 2.4% and 4.5% of patients in treatment 
with agomelatine at 50 mg, but not with agomelatine at 25 mg or with placebo [146,147]. These LFT 
increases were isolated, mainly within the first month of treatment, and no clinical signs of liver 
damage were found. A higher proportion of patients with LFT elevations had a history of cholecystitis, 
gallbladder disorder or hepatic steatosis. For these reasons, agomelatine is contraindicated in patients 
with hepatic impairment. Consequently, it is a condition of treatment that LFTs should be performed 
for all patients at the initiation of treatment, then periodically after around six, 12 and 24 weeks and, 
thereafter, when clinically indicated [148]. If an increase in serum transaminases occurs, blood liver 
function analyses must to be repeated within 48 h, and it is necessary to discontinue the therapy if such 
an increase is three-times the upper limit of the normal range. The liver function test must be evaluated 
until serum transaminases return to the normal range.  
6.11. Limitations of Agomelatine Trials in Major Depressive Disorder 
Despite the majority of positive study results regarding agomelatine in the treatment of MDD, 
limitations of the reviewed studies should be considered. For example, inclusion and exclusion criteria 
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employed in the trials may have somewhat favored individuals who would respond to treatment. In 
fact, patients with a recent history of suicidality, electroconvulsive therapy, psychotic features or 
recent substance abuse were excluded in almost all studies. Moreover, most of the studies with an 
active comparator arm employed relatively low dosages of venlafaxine, paroxetine, sertraline and 
fluoxetine, which may have improved the relative efficacy of agomelatine [149]. Four trials with an 
active comparator arm did not have a placebo group [117,118,140,141]. These studies reported high 
rates of response, but the lack of placebo groups makes it difficult to place the high rates of response in 
a proper context. In addition to high response rates, two studies reported that the differences in 
antidepressant efficacy were not statistically significant when comparing agomelatine with venlafaxine 
or paroxetine [117,119]. In both of the studies, antidepressant efficacy was only a secondary outcome, 
and no clear description of statistical power was provided. Thus, the similar rates of antidepressant 
efficacy between agomelatine and the comparator agents may have been affected by the relatively low 
dose of venlafaxine (75–150 mg/day) and paroxetine (20 mg/day) and by an inadequate power when 
comparing antidepressant efficacy between these agents.  
However, despite these shortcomings, the placebo-controlled trials reported improvements in 
depression rating scale scores (i.e., 2–3 points) that were similar to responses reported to the Food and 
Drug Administration involving a number of agents approved for the treatment of MDD [139]. In 2006, 
agomelatine was denied marketing authorization in Europe, due to a reported lack of efficacy [148]. 
Since that time, additional studies demonstrating agomelatine’s efficacy have been published, and in 
November 2008, the committee for medicinal products for human use of the European Medicines 
Agency provided marketing authorization for treating MDD episodes in adults with agomelatine [120]. 
7. Conclusions 
MDD is one of the most disabling and common psychiatric disorders. It should be noted that some 
unpublished studies reported no significant differences in HAMD and CGI scores between agomelatine vs. 
placebo compared to fluoxetine/paroxetine vs. placebo groups, but no significant differences in relapse 
rates were also shown when agomelatine was compared to placebo. On the other hand, published data 
reported agomelatine efficacy, compared to placebo and based on HAMD, in the treatment of major 
depressive disorder. Howland et al. [150,151] have suggested that a publication bias may be present, 
as the favorable studies have generally been published and unfavorable studies have generally  
not been published. When compared to other antidepressants (venlafaxine, sertraline, fluoxetine and 
escitalopram), agomelatine showed, at least, comparable efficacy.  
The efficacy of agomelatine on the dimension of anhedonia may be of particular importance in the 
treatment of MDD with anhedonic features. In fact, on the basis of SHAPS scores, agomelatine was 
reported to be effective in the treatment of anhedonia. In particular, agomelatine showed a more 
relevant reduction in SHAPS scores when compared to venlafaxine after eight weeks of treatment. 
Some studies reported that agomelatine was similar to sertraline and superior to venlafaxine and 
escitalopram in the improvement of sleep parameters in patients with MDD. Lower deterioration in the 
domains of desire and orgasm of the Sex Effects Questionnaire were reported when agomelatine was 
compared to venlafaxine. In healthy male volunteers, agomelatine was shown to have better sexual 
acceptability than paroxetine. 
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Discontinuation rates for any cause were fewer for agomelatine than venlafaxine, sertraline and 
fluoxetine. Moreover, data suggest that agomelatine is not associated with discontinuation symptoms, 
even if this potential side effect warrants further investigation, especially regarding long-term risks. 
About responder and remission rates, data are contrasting, even if agomelatine was largely used in 
difficult-to-treat or refractory patients. The incidence of relapse over six months was significantly 
lower with agomelatine. 
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